


Expanding Pharmaceutical Research Driving The Small Molecule Targeted Therapy Market 2026

The Business Research Company's Expanding Pharmaceutical Research Driving The Small Molecule Targeted Therapy Market 2026

LONDON, GREATER LONDON, UNITED KINGDOM, March 17, 2026

/EINPresswire.com/ -- "Small Molecule Targeted Therapy market to surpass \$118 billion in 2030. Within the broader Pharmaceuticals industry, which is expected to be \$2,513 billion by 2030, the Small Molecule Targeted Therapy market is estimated to account for nearly 5% of the total market value.



Which Will Be The Biggest Region In The Small Molecule Targeted Therapy Market in 2030



Expected to grow to \$120.64 billion in 2030 at a compound annual growth rate (CAGR) of 9.3%"

The Business Research Company

North America will be the largest region in the small molecule targeted therapy market in 2030, valued at \$49 billion. The market is expected to grow from \$32 billion in 2025 at a compound annual growth rate (CAGR) of 9%. The strong growth can be attributed to high oncology prevalence rates, strong presence of leading pharmaceutical and biotechnology companies, robust clinical trial activity, favorable reimbursement frameworks, accelerated regulatory approvals, and increasing adoption

of precision medicine and biomarker-driven treatment approaches across the United States and Canada.

Which Will Be The Largest Country In The Global Small Molecule Targeted Therapy Market In 2030?

The USA will be the largest country in the small molecule targeted therapy market in 2030, valued at \$44 billion. The market is expected to grow from \$29 billion in 2025 at a compound


annual growth rate (CAGR) of 9%. The strong growth can be attributed to rising cancer incidence rates, strong domestic presence of leading pharmaceutical innovators, high adoption of targeted oncology therapies, increasing biomarker testing and companion diagnostic utilization, robust clinical trial pipelines, favorable reimbursement policies, and continued investment in precision medicine and translational research initiatives across the country.

Request A Free Sample Of The Small Molecule Targeted Therapy Market Report

https://www.thebusinessresearchcompany.com/sample_request?id=28332&type=smp&utm_source=EINPresswire&utm_medium=Paid&utm_campaign=Mar_PR

What Will Be The Largest Segment In The Small Molecule Targeted Therapy Market In 2030?

The small molecule targeted therapy market is segmented by type of therapy into chemotherapy, targeted therapy, and immunotherapy. The targeted therapy market will be the largest segment of the small molecule targeted therapy market segmented by type of therapy, accounting for 46% or \$55 billion of the total in 2030. The targeted therapy market will be supported by the increasing adoption of biomarker-driven treatment approaches, rising prevalence of mutation-specific cancers, strong clinical pipeline of next-generation kinase and pathway inhibitors, improved survival outcomes compared to conventional chemotherapy, expanding use of companion diagnostics, favorable regulatory approvals for precision medicines, and growing investment in oncology-focused research and development. The small molecule targeted therapy market is segmented by mechanism of action into kinase inhibitors, proteasome inhibitors, cell-cycle or CDK inhibitors, angiogenesis inhibitors, apoptosis inducers or BCL2 modulators, epigenetic modulators, RNA-targeting small molecules, and other mechanisms of action. The small molecule targeted therapy market is segmented by route of administration into oral, intravenous, and subcutaneous. The small molecule targeted therapy market is segmented by indication into oncology, autoimmune diseases, inflammatory diseases, and other diseases. The small molecule targeted therapy market is segmented by end-user or distribution channel into hospitals & oncology centers, specialty clinics or ambulatory surgical centers, retail and specialty



pharmacies, and contract research organizations.

The small molecule targeted therapy market is segmented by mechanism of action into kinase inhibitors, proteasome inhibitors, cell-cycle or CDK inhibitors, angiogenesis inhibitors, apoptosis inducers or BCL2 modulators, epigenetic modulators, RNA-targeting small molecules, and other mechanisms of action.

The small molecule targeted therapy market is segmented by route of administration into oral, intravenous, and subcutaneous.

The small molecule targeted therapy market is segmented by indication into oncology, autoimmune diseases, inflammatory diseases, and other diseases.

The small molecule targeted therapy market is segmented by end-user or distribution channel into hospitals & oncology centers, specialty clinics or ambulatory surgical centers, retail and specialty pharmacies, and contract research organizations.

What Is The Expected CAGR For The Small Molecule Targeted Therapy Market Leading Up To 2030?

The expected CAGR for the small molecule targeted therapy market leading up to 2030 is 9%.

What Will Be The Growth Driving Factors In The Global Small Molecule Targeted Therapy Market In The Forecast Period?

The rapid growth of the global small molecule targeted therapy market leading up to 2030 will be driven by the following key factors that are expected to reshape preclinical research methodologies, laboratory infrastructure standards, regulatory compliance frameworks, and innovation across global biomedical and life sciences ecosystems.

Growing Demand For Personalized Medicine - The growing demand for personalized medicine is expected to become a key growth driver for the small molecule targeted therapy market by 2030. The increasing adoption of personalized medicine is significantly fueling the growth of the small molecule targeted therapy market, as these therapies are specifically developed to address molecular abnormalities unique to an individual's disease profile. Personalized treatment strategies leverage genetic insights and biomarker data to customize therapeutic interventions, and small molecules can be precisely designed to interact with identified molecular targets in patients. This targeted approach improves therapeutic efficacy, reduces adverse effects, and ultimately enhances overall patient outcomes. As a result, the growing demand for personalized medicine is anticipated to contribute to 2.2% annual growth in the market.

Advancements In AI-Driven Drug Discovery - The advancements in AI-driven drug discovery is expected to emerge as a major factor driving the expansion of the small molecule targeted therapy market by 2030. Advancements in AI-driven drug discovery are propelling the expansion of the small molecule targeted therapy market by enabling quicker and more accurate

identification of therapeutic targets and promising lead compounds. Artificial intelligence tools process large-scale biological and chemical datasets to predict molecular interactions and refine drug design, substantially shortening development timelines and lowering research costs. In addition, machine learning models streamline hit-to-lead optimization and enable early prediction of drug efficacy and safety profiles. These capabilities enhance clinical trial success rates and further strengthen the development of personalized treatment strategies. Consequently, the advancements in AI-driven drug discovery are projected to contribute to around 2.0% annual growth in the market.

Expanding Applications In Rare Diseases - The expanding applications in rare diseases is expected to act as a key growth catalyst for the small molecule targeted therapy market by 2030. The expanding application of small molecule therapies in rare diseases is significantly contributing to the growth of the small molecule targeted therapy market by creating new opportunities for highly personalized treatment approaches. Many rare disorders arise from distinct genetic mutations or specific molecular abnormalities, which can be precisely targeted or modulated using small molecule drugs. Progress in genomics, molecular diagnostics, and biomarker identification has further facilitated the development of these targeted therapies. Additionally, supportive regulatory frameworks, including orphan drug designations and related incentives, are encouraging greater investment and innovation in this segment. Therefore, the expanding applications in rare diseases is projected to contribute to approximately 1.5% annual growth in the market.

Access The Detailed Small Molecule Targeted Therapy Market Report Here

https://www.thebusinessresearchcompany.com/report/small-molecule-targeted-therapy-global-market-report?utm_source=EINPresswire&utm_medium=Paid&utm_campaign=Mar_PR

What Are The Key Growth Opportunities In The Small Molecule Targeted Therapy Market In 2030?

The most significant growth opportunities are anticipated in the chemotherapy market, the targeted therapy market, and the immunotherapy market. Collectively, these segments are projected to contribute over \$39 billion in market value by 2030, driven by rising global cancer incidence, continuous expansion of precision oncology pipelines, increasing approvals of novel small molecule inhibitors, growing adoption of combination therapy regimens, advancements in biomarker testing and companion diagnostics, and strong investment in oncology research and clinical trials. This surge reflects the accelerating focus on improving treatment efficacy, minimizing off-target toxicity, extending patient survival rates, and advancing personalized medicine approaches, fuelling transformative growth within the broader oncology therapeutics industry.

The chemotherapy market is projected to grow by \$9 billion, the targeted therapy market by \$19 billion, and the immunotherapy market by \$11 billion over the next five years from 2025 to 2030.

Learn More About The Business Research Company

The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. We have published over 17,500 reports across 27 industries and 60+ geographies. Our research is powered by 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders.

We provide continuous and custom research services, offering a range of specialized packages tailored to your needs, including Market Entry Research Package, Competitor Tracking Package, Supplier & Distributor Package and much more.

Disclaimer: Please note that the findings, conclusions and recommendations that TBRC Business Research Pvt Ltd delivers are based on information gathered in good faith from both primary and secondary sources, whose accuracy we are not always in a position to guarantee. As such TBRC Business Research Pvt Ltd can accept no liability whatever for actions taken based on any information that may subsequently prove to be incorrect. Analysis and findings included in TBRC reports and presentations are our estimates, opinions and are not intended as statements of fact or investment guidance.

Contact Us:

The Business Research Company

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email: info@tbrc.info

Follow Us On:

LinkedIn: <https://in.linkedin.com/company/the-business-research-company>"

Oliver Guirdham

The Business Research Company

+44 7882 955267

info@tbrc.info

Visit us on social media:

[LinkedIn](#)

[Facebook](#)

[X](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/899765984>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable

in today's world. Please see our Editorial Guidelines for more information.

© 1995-2026 Newsmatics Inc. All Right Reserved.